Life Sciences Growth June 10, 2022Creating value in medtech has become a challenge, particularly for large diversified companies. As an example, the top 30 cross-category companies in the industry have underperformed the S&P over one-, three-, and five-year periods. We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com To read the article, see “Accelerating growth in medtech: The next surge in portfolio moves,” May 10, 2022.